PMID- 34752683
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20220531
IS  - 2050-4527 (Electronic)
IS  - 2050-4527 (Linking)
VI  - 10
IP  - 2
DP  - 2022 Feb
TI  - The MCP-1 rs1024611 and MTHFR rs1801133 gene variations and expressions in 
      alopecia areata: A pilot study.
PG  - 209-217
LID - 10.1002/iid3.564 [doi]
AB  - BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) is highly expressed by 
      lymphocytes at skin sites affected by alopecia areata (AA). Variations in MCP-1 
      as well as in methylene-tetrahydrofolate reductase (MTHFR), a key enzyme related 
      to many inflammatory pathologies, have been associated with several autoimmune 
      disorders. This study was designed to test a possible association between MCP-1 
      and MTHFR variations and altered expression of their genes and the risk of AA. 
      METHODS: Blood samples of patients (60) suffering from AA as well as healthy 
      subjects (60) were collected. Gene expression levels of MCP-1 and MTHFR were 
      evaluated by real-time reverse-transcription polymerase chain reaction analysis. 
      Moreover, MCP-1 rs1024611 (A-2518G) and MTHFR rs1801133 (C677T) polymorphisms 
      were genotyped by using polymerase chain reaction-restriction fragment length 
      polymorphism assays. RESULTS: In contrast to MCP-1, the MTHFR gene expression was 
      found to be significantly higher in patients than in controls. Further 
      stratification of the patients revealed that polymorphic genotypes in MCP-1 
      (AG + GG) and MTHFR (CT + TT) could significantly alter gene expression levels. 
      Elevation of MCP-1 expression was significantly associated with the total number 
      of variant MCP-1 and MTHFR alleles. However, no statistically significant 
      difference was noticed in the genotypic distribution of MCP-1 and MTHFR 
      variations between patients and controls. CONCLUSION: In summary, despite MCP-1 
      rs1024611 and MTHFR rs1801133 variations are not associated with AA risk, they 
      may implicate the disease pathogenesis by influencing MCP-1 activity.
CI  - (c) 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & 
      Sons Ltd.
FAU - Tabatabaei-Panah, Pardis-Sadat
AU  - Tabatabaei-Panah PS
AD  - Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran.
FAU - Moravvej, Hamideh
AU  - Moravvej H
AD  - Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Hajihasani, Mahsa
AU  - Hajihasani M
AD  - Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran.
FAU - Mousavi, Mahsa
AU  - Mousavi M
AD  - Department of Biology, East Tehran Branch, Islamic Azad University, Tehran, Iran.
FAU - Ludwig, Ralf J
AU  - Ludwig RJ
AD  - Lubeck Institute of Experimental Dermatology, University of Lubeck, Germany.
FAU - Akbarzadeh, Reza
AU  - Akbarzadeh R
AUID- ORCID: 0000-0001-7668-702X
AD  - Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
AD  - Lubeck Institute of Experimental Dermatology, University of Lubeck, Germany.
AD  - Institute of Clinical Chemistry and Laboratory Medicine, University Medical 
      Center Hamburg-Eppendorf, Hamburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20211109
PL  - England
TA  - Immun Inflamm Dis
JT  - Immunity, inflammation and disease
JID - 101635460
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - EC 1.5.1.20 (MTHFR protein, human)
RN  - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2))
SB  - IM
MH  - *Alopecia Areata/genetics
MH  - *Chemokine CCL2/genetics
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - *Methylenetetrahydrofolate Reductase (NADPH2)/genetics
MH  - Pilot Projects
MH  - Polymorphism, Single Nucleotide
PMC - PMC8767509
OTO - NOTNLM
OT  - MCP-1
OT  - MTHFR
OT  - alopecia areata
OT  - gene expression
OT  - polymorphism
COIS- The authors declare that there are no conflict of interests.
EDAT- 2021/11/10 06:00
MHDA- 2022/04/05 06:00
PMCR- 2021/11/09
CRDT- 2021/11/09 17:38
PHST- 2021/10/31 00:00 [revised]
PHST- 2021/08/02 00:00 [received]
PHST- 2021/11/02 00:00 [accepted]
PHST- 2021/11/10 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
PHST- 2021/11/09 17:38 [entrez]
PHST- 2021/11/09 00:00 [pmc-release]
AID - IID3564 [pii]
AID - 10.1002/iid3.564 [doi]
PST - ppublish
SO  - Immun Inflamm Dis. 2022 Feb;10(2):209-217. doi: 10.1002/iid3.564. Epub 2021 Nov 
      9.